Zydus Lifesciences Q2 FY27 Profit Falls 26.6% Despite Revenue Gain

Zydus Lifesciences Ltd reported consolidated revenue growth of 29.2% to ₹7,909.6 crore in Q2 FY27, but net profit fell 26.6% year on year to ₹925.5 crore as expenses increased and operating margins contracted. The July-September results underline the difference between strong sales growth and pressure on quarterly profitability.

What did Zydus report for Q2 FY27?

Zydus reported revenue from operations of ₹7,909.6 crore for the quarter ended September 30, 2026, compared with ₹6,123.2 crore in the corresponding quarter of the previous year. Revenue was also above the ₹7,553 crore estimate cited in the supplied material. On a sequential basis, however, revenue declined 1.3%.

Consolidated net profit declined to ₹925.5 crore from ₹1,260.9 crore a year earlier. Profit before tax fell 25.5% year on year to ₹1,261.7 crore. EBITDA was ₹1,894.5 crore, down 6% from ₹2,015 crore in Q2 FY26, while the EBITDA margin contracted to 24.0% from 32.9% a year earlier. The margin was broadly stable against 24.1% in Q1 FY27.

The board approved the unaudited quarterly and half-yearly results on November 4, 2026. Deloitte's limited-review conclusion on the financial results was unmodified, according to the information provided. The reported quarterly basic and diluted earnings per share were ₹9.28.

Why did Zydus profit decline despite higher revenue?

Zydus's profit decline followed a substantially faster rise in expenses than in revenue. Total expenses increased 51% year on year to ₹6,806.6 crore from ₹4,509 crore. This cost increase reduced operating leverage during a quarter in which the company continued to report expansion across several businesses.

The supplied material links profitability pressure to higher operating expenses and commercialisation investment, including preparations for the planned US launch of saroglitazar. The company also reported USFDA inspection observations at two facilities, although the provided information does not specify the observations, the facilities, or any financial effect.

The pharmaceutical business, comprising North America, India and International Markets formulations, accounted for 83% of sales. North America formulations revenue was ₹3,314.5 crore, up 21% year on year, supported by volume expansion in the base business, according to the supplied results summary. International Markets recorded 33% year-on-year growth, the fastest segment growth rate mentioned in the material.

How did Zydus's India formulations business perform?

Zydus's India formulations business generated ₹1,884.4 crore in Q2 FY27, an 18% increase from a year earlier and 3.8% growth sequentially. The business contributed 24% of consolidated revenue. Branded formulations grew 19%, while secondary sales increased 20% year on year.

The company said volume growth and new product launches accounted for around two-thirds of secondary-sales growth. It also reported market-share gains across cardiology, diabetology, respiratory, dermatology, gastrointestinal and anti-infectives therapies, along with oncology and nephrology.

The mix of chronic and sub-chronic products stood at 56.9% of the portfolio, based on AWACS MAT September 2026 data. This represented an improvement of 450 basis points over four years. A higher chronic-product mix can be relevant for pharmaceutical companies because these therapies generally involve recurring prescriptions, though the quarterly release does not provide a separate profitability measure for this portfolio.

Consumer wellness also contributed to domestic growth. The business expanded 29% year on year, with skin and hair care increasing 37% and food and nutrition rising 25%. These figures show that growth was not limited to prescription formulations during the quarter.

What do the results mean for investors and operations?

Zydus's Q2 FY27 performance shows strong sales momentum but a weaker earnings conversion than in the comparable quarter last year. Revenue increased by ₹1,786.4 crore year on year, while EBITDA declined by ₹120.5 crore and net profit fell by ₹335.4 crore. The gap reflects the importance of tracking costs, launches and margins alongside top-line growth.

The supplied reports said Zydus shares fell more than 4% after the results presentation, as market attention focused on the profit decline and margin compression. The available information does not establish a direct causal link between every element of the results and the share-price movement, but the earnings release placed the margin decline alongside higher expenses and investment requirements.

For investors, the 24% EBITDA margin is an important reference point because it was nearly unchanged sequentially but below the 32.9% reported a year earlier. Revenue growth exceeded the reported market estimate, and EBITDA of ₹1,894.5 crore was above the cited ₹1,723 crore estimate. Still, the year-on-year fall in EBITDA and profit remains central to assessing the quarter.

What other developments did Zydus disclose?

Zydus completed the acquisition of Sterling Biotech's API business on November 2, 2026. The transaction occurred shortly before the company announced its second-quarter results. The supplied material does not provide the acquisition value, integration timetable or expected contribution to revenue and profit.

For the half year ended September 30, 2026, revenue from operations was ₹15,926.6 crore and net profit after tax was ₹1,938.5 crore. The company reported cash and cash equivalents of ₹6,692 crore at September 30, down from ₹8,552 crore at the beginning of the half year. The material attributes the reduction partly to investing activity, including acquisition payments and contingent consideration, but the figures included in the source are not sufficiently consistent to state a reliable aggregate transaction amount.

The combination of acquisitions, product commercialisation spending and regulatory disclosures will remain relevant to operating execution. The current release confirms the acquisition completion and the presence of USFDA observations, but does not disclose their future operational or financial consequences.

Conclusion

Zydus delivered 29.2% revenue growth in Q2 FY27, led by its pharmaceutical businesses, India formulations and consumer wellness portfolio. However, a 51% increase in total expenses weighed on profitability, resulting in a 26.6% decline in net profit and an EBITDA margin of 24.0%, compared with 32.9% a year earlier.

The next areas to watch are the financial and operational contribution from Sterling Biotech's API business, the planned US launch of saroglitazar, and any further information on the USFDA inspection observations. Investors will also monitor whether revenue growth translates into improved margins as commercialisation and operating costs evolve.